Recent Therapeutic Advances in the Treatment of Colorectal Cancer.
Columbus, United States. In Annu Rev Med, 09 Nov 2014
Molecular profiling of metastatic colorectal cancer (including mutational analysis for KRAS, NRAS, BRAF, PIK3CA, and others) has become increasingly important for identification of prognostic and predictive biomarkers, as well as for insights into the biology that drives the tumor.
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma.
Bergamo, Italy. In N Engl J Med, 29 Oct 2014
UNLABELLED: Background The combined inhibition of BRAF and MEK is hypothesized to improve clinical outcomes in patients with melanoma by preventing or delaying the onset of resistance observed with BRAF inhibitors alone.
Novel Approaches in Anaplastic Thyroid Cancer Therapy.
Madison, United States. In Oncologist, 26 Oct 2014
This review will cover several cellular signaling pathways and mechanisms, including RET/PTC, RAS, BRAF, Notch, p53, and histone deacetylase, which are identified to play roles in the transformation and dedifferentiation process, and therapies that target these pathways.
eIF4F is a nexus of resistance to anti-BRAF and anti-MEK cancer therapies.
Villejuif, France. In Nature, 04 Oct 2014
In BRAF(V600)-mutant tumours, most mechanisms of resistance to drugs that target the BRAF and/or MEK kinases rely on reactivation of the RAS-RAF-MEK-ERK mitogen-activated protein kinase (MAPK) signal transduction pathway, on activation of the alternative, PI(3)K-AKT-mTOR, pathway (which is ERK independent) or on modulation of the caspase-dependent apoptotic cascade.
Systemic treatment for BRAF-mutant melanoma: where do we go next?
Sydney, Australia. In Lancet Oncol, Aug 2014
After decades of treatment failure for metastatic melanoma, the development of BRAF inhibitors was highly anticipated to dramatically improve outcomes for patients with oncogene-addicted BRAF-mutant metastatic melanoma.